Development of In Vitro Assays for Advancing Radioimmunotherapy against Brain Tumors

Development of In Vitro Assays for Advancing Radioimmunotherapy against Brain Tumors

Glioblastoma (GBM) is the most common primary brain tumor. Due to high resistance to treatment, local invasion, and a high risk of recurrence, GBM patient prognoses are often dismal, with median survival around 15 months. The current standard of care is threefold: surgery, radiation therapy, and che...

Full description

Bibliographic Details
Main Authors: Yohan Walter, Anne Hubbard, Allie Benoit, Erika Jank, Olivia Salas, Destiny Jordan, Andrew Ekpenyong
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Biomedicines
Subjects:
glioblastoma
immunotherapy
radiotherapy
brain cancers
radioimmunotherapy
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2227-9059/10/8/1796

Internet

https://www.mdpi.com/2227-9059/10/8/1796

Similar Items